Shionogi USA, Inc. - Other Areas

About Shionogi USA

Development Portfolio

Marketed Products

Newsroom

Colorized scanning electron micrograph of fat cells

Other Development Activities

Compound	Development Phase	Method of action	Indication(s)
S-2367	Phase IIb	NPY Y5 receptor antagonist	Obesity
S-777469	Phase I	Cannabinoid 2 receptor agonist	Atopic Dermatitis
S-555739	Phase I	Prostoglandin D2 receptor antagonist	Allergic Rhinitis
S-888711	Phase I	Thrombopoietin receptor agonist	Thromboeytopenia

Spotlight on S-2367

S-2367 is an oral, centrally acting anti-obesity drug which reduces appetite and enhances energy expenditure. Findings from a Phase I single-dose study indicate that S-2367 is very well tolerated with a low incidence of adverse events. S-2367 is currently in Phase II clinical testing for the treatment of obesity.

Shionogi USA is currently evaluating several other innovative compounds from Shionogi Research Laboratories in Japan to identify additional candidates for clinical development in the US. To see the Shionogi Research Laboratory development pipeline please click here.